Home » Topics » Neurology/psychiatric, BioWorld Science

Neurology/psychiatric, BioWorld Science
RSS

JT discloses new compounds for Alzheimer's disease and other CNS disorders

Dec. 4, 1996

New 5-HT1D antagonists from SmithKline Beecham

Dec. 4, 1996

McNeil describes new antipsychotic compounds

Dec. 4, 1996

Avonex progresses toward European approval

Dec. 3, 1996

New hope for muscular dystrophy sufferers

Dec. 3, 1996

Antiepileptic drug from Neurogen licensed to Wyeth-Ayerst

Dec. 2, 1996

New anxiolytic under development at Parke-Davis

Dec. 2, 1996

Antiepileptic agent reported by Parke-Davis

Dec. 2, 1996

Ethical's sustained-release morphine sublicensed for Canada

Dec. 2, 1996

CytoTherapeutics and Genentech sign new CNS therapeutics agreement

Nov. 29, 1996

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 6, 2025.
MJFF grant supports Bexorg’s translational biomarker work
BioWorld Science
Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...
REST emerges as biomarker in ALS, knockdown improves ALS symptoms
BioWorld Science
About 10% of amyotrophic lateral sclerosis (ALS) cases result from inherited genetic mutations, with about 20% of them attributed to mutations in the gene...
Serotonin receptor modulators for the treatment of OUD
BioWorld Science
Opioid use disorder (OUD) causes high morbidity and mortality rates, with fentanyl driving unprecedented overdose rates. Researchers from the University of...
KLF15 shows potential as marker, target for cholangiocarcinoma
BioWorld Science
Researchers at the Biodonostia Health Research Institute reported on the role of KLF15 in cholangiocarcinogenesis and its potential as a therapeutic target in...